Penbutolol

Penbutolol
Klinički podaci
Prodajno ime	Betapressin, Levatol, Levatolol, Lobeta
Drugs.com	Monografija
Način primene	Oralno
Identifikatori
CAS broj	36507-48-9
ATC kod	C07AA23 (WHO)
PubChem	CID 37464
DrugBank	DB01359
ChemSpider	34369
ChEMBL	CHEMBL1290

Penbutolol je organsko jedinjenje, koje sadrži 18 atoma ugljenika i ima molekulsku masu od 291,428 Da.^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]

Osobine

Osobina	Vrednost
Broj akceptora vodonika	3
Broj donora vodonika	2
Broj rotacionih veza	7
Particioni koeficijent^[9] (ALogP)	3,6
Rastvorljivost^[10] (logS, log(mol/L))	-5,0
Polarna površina^[11] (PSA, Å²)	41,5

Reference

^ Maurer, H. H.; Tenberken, O.; Kratzsch, C.; Weber, A. A.; Peters, F. T. (новембар 2004). „Screening for library-assisted identification and fully validated quantification of 22 beta-blockers in blood plasma by liquid chromatography-mass spectrometry with atmospheric pressure chemical ionization”. J Chromatogr A. 1058 (1–2): 169—181. PMID 15595665. doi:10.1016/S0021-9673(04)01308-1.
^ Aguirre C, Rodriguez-Sasiain JM, Calvo R (1994). „Decrease in penbutolol protein binding as a consequence of treatment with some alkylating agents”. Cancer Chemother Pharmacol. 34 (1): 86—88. PMID 8174208. doi:10.1007/BF00686119. . .
^ Cutrufo, C.; Bortot, L.; Giachetti, A.; Manzini, S. (1992). „Differential effects of various xanthines on pentylenetetrazole-induced seizures in rats: An EEG and behavioural study”. Eur J Pharmacol. 222 (1): 121—127. PMID 1468487. doi:10.1016/0014-2999(92)90454-C. Непознати параметар |DUPLICATE_pmid= игнорисан (помоћ)
^ Pepe, S.; Scalici, G.; d'Angelo, A.; Curiale, B.; Corrao, S.; Agnello, C. (јун 1990). „Validity of the use of penbutolol in essential arterial hypertension”. Minerva Med. 81 (6): 471—473. PMID 2359502.
^ Frishman, W. H.; Covey, S. (1990). „Penbutolol and carteolol: Two new beta-adrenergic blockers with partial agonism”. J Clin Pharmacol. 30 (5): 412—421. PMID 2189902. doi:10.1002/j.1552-4604.1990.tb03479.x.
^ Martínez Jordá, R.; Aguirre, C.; Calvo, R.; Rodríguez-Sasiaín, J. M.; Erill, S. (1990). „Decrease in penbutolol central response as a cause of changes in its serum protein binding”. J Pharm Pharmacol. 42 (3): 164—166. PMID 1974610. doi:10.1111/j.2042-7158.1990.tb05377.x.
^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
^ Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
^ Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.
^ Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
^ Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

Literatura

Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.

Spoljašnje veze

Penbutolol Архивирано на веб-сајту Wayback Machine (16. фебруар 2014)

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] Maurer, H. H.; Tenberken, O.; Kratzsch, C.; Weber, A. A.; Peters, F. T. (новембар 2004). „Screening for library-assisted identification and fully validated quantification of 22 beta-blockers in blood plasma by liquid chromatography-mass spectrometry with atmospheric pressure chemical ionization”. J Chromatogr A. 1058 (1–2): 169—181. PMID 15595665. doi:10.1016/S0021-9673(04)01308-1.

[2] Aguirre C, Rodriguez-Sasiain JM, Calvo R (1994). „Decrease in penbutolol protein binding as a consequence of treatment with some alkylating agents”. Cancer Chemother Pharmacol. 34 (1): 86—88. PMID 8174208. doi:10.1007/BF00686119. . .

[3] Cutrufo, C.; Bortot, L.; Giachetti, A.; Manzini, S. (1992). „Differential effects of various xanthines on pentylenetetrazole-induced seizures in rats: An EEG and behavioural study”. Eur J Pharmacol. 222 (1): 121—127. PMID 1468487. doi:10.1016/0014-2999(92)90454-C. Непознати параметар |DUPLICATE_pmid= игнорисан (помоћ)

[4] Pepe, S.; Scalici, G.; d'Angelo, A.; Curiale, B.; Corrao, S.; Agnello, C. (јун 1990). „Validity of the use of penbutolol in essential arterial hypertension”. Minerva Med. 81 (6): 471—473. PMID 2359502.

[5] Frishman, W. H.; Covey, S. (1990). „Penbutolol and carteolol: Two new beta-adrenergic blockers with partial agonism”. J Clin Pharmacol. 30 (5): 412—421. PMID 2189902. doi:10.1002/j.1552-4604.1990.tb03479.x.

[6] Martínez Jordá, R.; Aguirre, C.; Calvo, R.; Rodríguez-Sasiaín, J. M.; Erill, S. (1990). „Decrease in penbutolol central response as a cause of changes in its serum protein binding”. J Pharm Pharmacol. 42 (3): 164—166. PMID 1974610. doi:10.1111/j.2042-7158.1990.tb05377.x.

[7] Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.

[8] Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.

[9] Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.

[10] Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.

[11] Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]